MEDI4736 Alone and in Combination With Tremelimumab or AZD9150 in Adult Subjects With Relapsed/Refractory DLBCL (D4190C00023)

Part of paid clinical trials in La Jolla, California.

Sponsor
MedImmune LLC
Study ID
NCT02549651
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • MEDI4736 — DRUG
    MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
  • tremelimumab — DRUG
    Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
  • AZD9150 — DRUG
    AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion

Study Details

The purpose of this study is to evaluate the safety, tolerability, and efficacy of MEDI4736 (durvalumab) alone and in combination with either tremelimumab or AZD9150 in adult subjects with relapsed or refractory dIffuse large B-cell lymphoma.

Key Dates

Start date
Jul 13, 2016
Status verified
Feb 2019
Primary completion
Feb 4, 2019
Completion
Feb 4, 2019

Study Design

Enrollment
32 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: MEDI4736
  • Experimental: MEDI4736 and tremelimumab
  • Experimental: MEDI4736 and AZD9150

Primary Outcome Measure

Number of subjects reporting adverse events and number (percentage) of subjects reporting serious adverse events [ Time Frame: Screening through 90 days after the last dose of study medication ]

Locations (8)

FacilityCityStateZIPSite coordinators
Research SiteLa JollaCalifornia92093-
Research SiteBaltimoreMaryland21201-
Research SiteAlbuquerqueNew Mexico87131-
Research SiteDurhamNorth Carolina27710-
Research SiteCharlestonSouth Carolina29425-
Research SiteDallasTexas75390-
Research SiteHoustonTexas77030-
Research SiteMilwaukeeWisconsin53226-

Find similar trials in La Jolla, CA

By research site
Research Site· La Jolla, CAResearch Site· Baltimore, MDResearch Site· Albuquerque, NMResearch Site· Durham, NCResearch Site· Charleston, SCResearch Site· Dallas, TX

Related Studies